The AI clinical care debate is gaining momentum after the American Hospital Association submitted formal comments to the U.S. Department of Health and Human Services. In its AI clinical care response, the AHA called on federal officials to better coordinate policies and remove barriers that slow innovation in hospitals and health systems.
The comments came in response to an HHS request for information on how artificial intelligence is being adopted and used in clinical settings.
AHA AI Clinical Care Response Calls for Policy Alignment
In its AI clinical care recommendations, the AHA urged HHS to synchronize existing federal AI frameworks. According to the association, overlapping regulations and fragmented guidance risk creating confusion for hospitals trying to implement new tools.
The group asked the department to streamline oversight and avoid unnecessary duplication across agencies. By aligning policy efforts, hospitals could move faster in deploying AI solutions that improve patient outcomes.
The AHA also encouraged federal leaders to remove regulatory barriers that limit the development and use of AI-powered clinical tools. Hospital leaders argue that overly complex compliance requirements can delay innovation, even when technologies show promise.
Ensuring Safe and Effective AI Clinical Care
While advocating for flexibility, the AHA emphasized the need for safety. Its AI clinical care comments stressed that federal policy should ensure responsible use of AI in diagnosis, treatment planning and operational workflows.
The association asked HHS to adopt policies that protect patients while also encouraging innovation. Clear guardrails, it said, are essential to maintaining public trust as AI becomes more integrated into care delivery.
In addition, the AHA highlighted the importance of aligning financial incentives. Hospitals require proper reimbursement models and infrastructure support to expand AI in health care. Without sustainable funding pathways, adoption may remain uneven across regions and systems.
Building on Prior AI Policy Engagement
The AI clinical care response builds on several earlier federal consultations. The AHA has previously submitted feedback to multiple agencies regarding artificial intelligence oversight and reimbursement.
These include responses to:
- The Office of Science and Technology Policy on reducing regulatory burdens for AI.
- The Food and Drug Administration on evaluating AI-enabled medical devices.
- The Centers for Medicare & Medicaid Services on payment policies for AI tools under the CY 2026 Outpatient Prospective Payment System proposed rule and the CY 2026 Physician Fee Schedule proposed rule.
By referencing these earlier submissions, the AHA signaled a consistent push for coordinated federal leadership on AI governance.
AI Clinical Care and the Future of Hospitals
Artificial intelligence is increasingly used in medical imaging, predictive analytics, administrative automation and clinical decision support. Hospitals are also exploring AI to improve workflow efficiency and reduce clinician burnout.
However, expanding AI clinical care requires strong digital infrastructure. Many hospitals must upgrade data systems, cybersecurity protections and workforce training to safely integrate new technologies.
The AHA’s message to HHS was clear: policy must address both regulatory clarity and infrastructure readiness. Without both, large-scale AI adoption may stall.
Federal Focus on AI in Health Care
HHS issued its request for information as part of broader efforts to accelerate innovation in health services. Federal officials are seeking public input on how best to support responsible AI deployment while safeguarding patients.
The AHA’s AI clinical care response positions hospitals as active partners in shaping that policy framework. By urging coordination, regulatory relief and aligned incentives, the association hopes to create an environment where AI can enhance care rather than complicate it.
As artificial intelligence continues to reshape health systems, collaboration between policymakers and providers will likely determine how quickly these tools move from pilot programs to everyday clinical practice.
